Physician profile
David M Keller
NPI 1154409282
$1,969.95
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.68 · 2020: $90.50 · 2021: $421 · 2022: $749 · 2023: $614 · 2024: $17.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.89 | 2021-2023 | |
| Novo Nordisk INC | $246.95 | 2019-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $223.77 | 2020-2023 | Mounjaro, Lyumjev, Baqsimi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.35 | 2019-2023 | |
| Gilead Sciences, INC. | $120.85 | 2021-2023 | |
| Glaxosmithkline, LLC. | $118.77 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.16 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.83 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $84.97 | 2022-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $59.33 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $54.08 | 2021-2024 | Farxiga |
| Mannkind Corporation | $39.25 | 2023 | Afrezza |
| Neurocrine Biosciences, INC. | $33.55 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $32.89 | 2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $30.77 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $29.56 | 2022 | |
| Pfizer INC. | $28.30 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.98 | 2022 | |
| Corium, LLC | $25.97 | 2023 | Azstarys |
| Amgen INC. | $24.19 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $23.95 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $23.33 | 2023 | Auvelity |
| Amarin Pharma, INC. | $20.94 | 2020 | |
| Alkermes, INC. | $13.83 | 2022 | |
| Hologic Sales and Service, LLC | $13.33 | 2023 | Aptima |
| Janssen Pharmaceuticals, INC | $13.20 | 2023 | Xarelto |
| Allergan, INC. | $12.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.